Canaccord Genuity Initiates Coverage On Apotex Health with Buy Rating, Announces Price Target of C$42

Benzinga Newsdesk www.benzinga.com Positive 53.8%

Neg 0% Neu 0% Pos 53.8%

Canaccord Genuity analyst Tania Armstrong-Whitworth initiates coverage on Apotex Health (TSX:APTX) with a Buy rating and announces Price Target of C$42.